Latest press release
Sativex® improves symptoms of spasticity due to MS, study shows
Newbury, Berkshire, 2nd March 2011 – Results from a phase III clinical study published online yesterday in the European Journal of Neurology Early View [http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2010.03328.x/abstract]
showed that about half of all people with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to standard anti-spasticity therapy, find that adding Sativex® Oromucosal Spray (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)), to their existing medication can improve the debilitating symptoms of spasticity associated with MS.1
References available within the PDF
Clinical spokespeople
We have a number of MS specialist consultants and nurses across the UK who would be willing to talk to the media. To set up an interview please contact Liberation Communications.
Patient case studies
We have a number of patients with MS related spasticity across the UK who would be willing to talk to the media. To set up an interview please contact Liberation Communications.
Company spokespeople
For company spokesperson details please contact Liberation Communications.
B-roll
Click to download video footage of Sativex manufacturing and production.
About MS spasticity
Fast facts
- Multiple sclerosis (MS) is an incurable condition that affects approximately 100,000 people in the UK and is usually diagnosed between the ages of 20 and 40 years1,2
- > Damage occurs within the central nervous system
(CNS - brain and spinal cord)1 - > Spasticity is a common symptom associated with MS,3 affecting most people with MS at some point
- > In a survey, 84% of people with MS reported symptoms of spasticity4
- > Symptoms of spasticity include loss of mobility, painful spasms / cramps, stiffness and / or weakness of muscles5
- > There are a number of medicinal therapies commonly used to treat spasticity, although not all are licensed for this purpose6
- > Many have side effects which some people find difficult to tolerate at effective doses6
References available within the PDF
Sativex mode of action
To view this content, You need latest version of flash playerClick here to download free flash player now